(Sharecast News) - FD Technologies said in a trading update on Wednesday that it expected to achieve its revenue and adjusted EBITDA guidance for the financial year recently ended.
The AIM-traded firm said delivery of its accelerated growth strategy - announced in May last year - remained on track, enabling its KX division to achieve its target of 25% growth in exit annual recurring revenue.
That was driven by increasing take-up of the KX Insights platform, the company reported.
Combined with the recent announcement of its strategic partnership with Microsoft, the company said it entered the new financial year in a position to build on that momentum.
"I am pleased with our financial performance and the execution of our accelerated growth strategy in what was a year of transformation for the group," said chief executive officer Seamus Keating.
"I'm excited by the opportunities across our business as we win new customers and continue to develop our offering to drive value, performance and returns."
FD Technologies said it would report results for the financial year ended 28 February on 10 May.
At 0923 BST, shares in FD Technologies were up 9.34% at 2,400p.


(Alliance News) - FD Technologies PLC on Tuesday said revenue increased while its pretax loss widened in the 2025 financial year, as its takeover offe...


(Alliance News) - FD Technologies PLC on Thursday accepted a GBP570 million takeover offer from TA Associates Management LP, a day after talks between...


LONDON (Alliance News) - First Derivatives PLC Tuesday said non-executive Director David Anderson sold 10,000 shares at a price of 1,300 pence per sha...


LONDON (Alliance News) - First Derivatives PLC Thursday said it has opened its new Singapore office as it looks to build on its expansion into Asia. I...


Speciality drugs firm Alliance Pharma announced Monday that Executive Director Anthony Booley's share in the company was reduced by 300,000 shares aft...


LONDON (Alliance News) - First Derivatives PLC Monday said Non-Executive Director David Anderson sold 2,500 shares at a price of 1,356 pence per shar...


Advanced Medical Solutions: Panmure Gordon downgrades from buy to hold with a target price of 102p. Antofagasta: Canaccord Genuity cuts target price ...


Afren: Goldman Sachs moves target price from 260p to 270p and retains its strong buy recommendation. APR Energy: Citi raises target price from 1250p ...